Rodríguez-Otero, Paula
Mateos, María Victoria
Martínez-López, Joaquín
Martín-Calvo, Nerea http://orcid.org/0000-0001-7549-1455
Hernández, Miguel-Teodoro
Ocio, Enrique M.
Rosiñol, Laura
Martínez, Rafael
Teruel, Ana-Isabel
Gutiérrez, Norma C.
Bargay, Joan
Bengoechea, Enrique
González, Yolanda
de Oteyza, Jaime Pérez
Gironella, Mercedes
Encinas, Cristina
Martín, Jesús
Cabrera, Carmen
Palomera, Luis
de Arriba, Felipe
Cedena, María Teresa
Paiva, Bruno
Puig, Noemí
Oriol, Albert
Bladé, Joan
Lahuerta, Juan José
San Miguel, Jesús F.
Article History
Received: 19 April 2017
Revised: 26 December 2017
Accepted: 1 February 2018
First Online: 23 February 2018
Change Date: 8 March 2019
Change Type: Update
Change Date: 8 March 2019
Change Type: Correction
Change Details: Following the publication of this article, the author notes that the following information was missed from the acknowledgments section: This study wassupported by the Cooperative Research Thematic Networkgrants RD12/0036/0058 and RD12/0036/0046 of the Redde Cancer (Cancer Network of Excellence); Instituto deSalud Carlos III, Spain, Instituto de Salud Carlos III/SubdirecciónGeneral de Investigación Sanitaria part-financedby the European Regional Development Fund (FIS: PI12/01761; PI12/02311; PI13/01469; PI14/01867, G03/136;Sara Borrell: CD13/00340); Asociación Española Contra elCáncer (GCB120981SAN) and FEDER.The authors wish to apologise for any inconveniencecaused.
Change Details: Following the publication of this article, the author notes that the following information was missed from the acknowledgments section:
Compliance with ethical standards
:
: P.R.-O.: has served on the speaker’s bureau and as a member of advisory boards for Janssen and Celgene. M.-V.M.: has declared consultancy for: Janssen, Celgene, Takeda, Amgen. E.-M.O.: has declared consultancy for or honoraria from: Mundipharma, Celgene, Amgen, Novartis, Takeda, AbbVie, BMS, Janssen. B.P.: has declared grants and personal fees from Celgene, Janssen, Takeda, Sanofi, BMS and personal fees from Amgen and grants from Engmab. J.S.-M.: received honoraria as part of Advisory boards from Celgene, Novartis, Millenium, Janssen, Amgen, MSD, Sanofi, and BMS. A.O.: has served as a member of advisory boards for Janssen and Celgene. J.B.: received honoraria for lectures and advisory boards from Celgene and Janssen and grant support from Janssen. L.R.: received honoraria grom Janssen and Celgene. The remaining authors declare that they have no conflict of interest.